The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
Ian Flinn
Research Funding - Gilead Sciences
Eva Kimby
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Finbarr E. Cotter
Research Funding - Gilead Sciences
Francis J. Giles
Research Funding - Gilead Sciences
Ann Janssens
Research Funding - Gilead Sciences
Elisa Jacobsen Pulczynski
No relevant relationships to disclose
Loic Ysebeart
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Andrzej Pluta
Research Funding - Gilead Sciences
Jose Antonio Garcia Marco
Research Funding - Gilead Sciences
Kerry Taylor
Research Funding - Gilead Sciences
Carolyn Owen
Research Funding - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Maria Aiello
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Ronald L. Dubowy
Employment or Leadership Position - Gilead Sciences
Jeffrey Alan Jones
Research Funding - Gilead Sciences